Related Experiment Video

Updated: May 12, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Targeting 20-HETE producing enzymes in cancer - rationale, pharmacology, and clinical potential

Anna Alexanian1, Andrey Sorokin

  • 1Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Oncotargets and Therapy
|April 10, 2013
PubMed

Insights

Lipid mediator 20-Hydroxyeicosatetraenoic acid (20-HETE) fuels cancer growth. Inhibiting its production may offer new anticancer therapies for various cancers.

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Lipid mediator 20-Hydroxyeicosatetraenoic acid (20-HETE) synthesis and signaling are linked to cancer cell growth.
  • Elevated expression of 20-HETE-producing Cytochrome P450 (CYP4A/4F) genes is observed in multiple human cancers.

Purpose of the Study:

  • To investigate the role of 20-HETE in cancer progression.
  • To explore the therapeutic potential of targeting 20-HETE synthesis in cancer treatment.

Main Methods:

  • Utilizing in vitro and in vivo models to study cancer cell proliferation.
  • Employing selective inhibitors of CYP4A and CYP4F enzymes.

Main Results:

  • 20-HETE agonists enhance cancer cell proliferation.
  • Inhibitors of 20-HETE-producing enzymes block proliferation in glioblastoma, prostate, renal cell, and breast cancer cell lines.
  • CYP4A/4F gene expression is significantly upregulated in thyroid, breast, colon, and ovarian cancers.

Conclusions:

  • Targeting 20-HETE-producing enzymes presents a promising therapeutic strategy for various human cancers.
  • These findings lay the groundwork for developing novel anticancer treatments focused on 20-HETE pathways.
Keywords:
20-hydroxyeicosatetraenoic acidCYP4ACYP4FHET0016eicosanoids

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...